Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Stopped The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria were met. The termination was not due to safety concerns.
Conditions
Interventions
- DRUG: PF-05212377 (SAM-760)
- OTHER: Placebo
Sponsor
Pfizer